| R2 (95% CI) | P value | STE |
---|---|---|---|
Total population [5,6,7,8,9,10, 17,18,19,20,21,22,23,24, 34,35,36,37,38,39] | 0.96 | ||
 Sample size | 0.80 (0.49 to 0.99) | <  0.001 |  |
 Fixed effect | 0.82 (0.52 to 0.99) | <  0.001 |  |
 Random effect | 0.82 (0.52 to 0.99) | <  0.001 |  |
Phase 3 trials [5,6,7,8,9,10, 18,19,20, 22, 34,35,36, 38, 39] | 0.96 | ||
 Sample size | 0.82 (0.48 to 0.99) | <  0.001 |  |
 Fixed effect | 0.82 (0.49 to 0.99) | <  0.001 |  |
 Random effect | 0.83 (0.50 to 0.99) | <  0.001 |  |
Trials with overall included patients ≥ 200 [7, 10, 18,19,20, 36, 38, 39] | 0.93 | ||
 Sample size | 0.85 (0.41 to 0.99) | <  0.001 |  |
 Fixed effect | 0.86 (0.41 to 0.99) | <  0.001 |  |
 Random effect | 0.87 (0.44 to 0.99) | <  0.001 |  |
Trials with median follow-up ≥ 24 months [6, 7, 9, 10, 18,19,20,21,22,23, 34, 36, 38, 39] | 0.95 | ||
 Sample size | 0.80 (0.43 to 0.99) | <  0.001 |  |
 Fixed effect | 0.81 (0.45 to 0.99) | <  0.001 |  |
 Random effect | 0.80 (0.43 to 0.99) | <  0.001 |  |
Trials with adjuvant therapy versus observation [5,6,7,8,9, 20, 34, 35] | 0.81 | ||
 Sample size | 0.68 (0.17 to 0.99) | 0.006 |  |
 Fixed effect | 0.69 (0.18 to 0.99) | 0.005 |  |
 Random effect | 0.73 (0.22 to 0.99) | 0.003 |  |
Trials with adjuvant therapy versus adjuvant therapy [8, 17,18,19, 21,22,23,24, 36, 38, 39] | 0.96 | ||
 Sample size | 0.90 (0.59 to 0.99) | <  0.001 |  |
 Fixed effect | 0.93 (0.66 to 0.99) | <  0.001 |  |
 Random effect | 0.89 (0.58 to 0.99) | <  0.001 |  |